Secondary Logo

Journal Logo

Clinical Science

Definition of Immunological Nonresponse to Antiretroviral Therapy: A Systematic Review

Rb-Silva, Rita MDa,b,c; Goios, Ana PhDa,b; Kelly, Christine PhDd; Teixeira, Pedro PhDa,b; João, Cristina MD, PhDe,f; Horta, Ana MD, PhDa,b,g; Correia-Neves, Margarida PhDa,b,h

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: December 15, 2019 - Volume 82 - Issue 5 - p 452-461
doi: 10.1097/QAI.0000000000002157

Abstract

Erratum

In the December 15, 2019 issue of JAIDS Journal of Acquired Immune Deficiency Syndromes , in the article titled “Definition of Immunological Nonresponse to Antiretroviral Therapy: A Systematic Review,” 1 there were errors in the abstract and table.

In the “Results” section of the abstract, the sentence which ready “Most criteria use CD4 + T-cell counts as a surrogate, either as an absolute value before antiretroviral therapy initiation or as a change after a defined period of time,” should read “Most criteria use CD4 + T-cell counts as a surrogate, either as an absolute value or as a change after a defined period of time.”

In Table 3, there is a “5” missing in “CD4 + T-cell count < 00 cells/mL” (above the lines corresponding to C.64 and C.65). It should be “CD4 + T-cell count < 500 cells/mL”. Additionally, the text of the first column in criteria C.66, C.67, C.68, C.69 and C.71 should be aligned on the left, as they are independent criteria. Please see the corrected table below.

JAIDS Journal of Acquired Immune Deficiency Syndromes. 83(4):e28, April 1, 2020.

INTRODUCTION

Antiretroviral therapy (ART) transformed the course of HIV infection, improving patient prognosis, quality of life and life expectancy.1,2 After ART initiation, plasma viral load drops to undetectable levels in individuals with good adherence and without resistance-associated mutations,3 and CD4+ T-cell count increases rapidly initially, followed by a longer period of slower rise.4 Some authors describe a CD4+ T-cell count plateau, whereas others report increases even after several years of therapy, depending on different factors such as age, pre-ART CD4+ T-cell count, and viral load.5–8 However, some individuals are unable to restore satisfactory CD4+ T-cell counts despite full virologic suppression (usually defined as <50 copies/mL),9,10 and have higher mortality and morbidity.4,11 The proportion of individuals with unsatisfactory immunological recovery despite viral suppression has been reported to be between 9% and 45% depending on the cohorts and criteria used. However, the diversity of the criteria renders estimates on prevalence problematic.

In the absence of consensual criteria, it is difficult to compare and combine coherent and solid results from different research groups. In clinical trials aiming to improve CD4+ T-cell recovery,12–21 variability in selection criteria precludes definitive conclusions.22 Although difficult to achieve, a consensual definition is mandatory to compare and combine data from distinct studies/cohorts.

We here analyze the diversity in terminologies and criteria applied to people living with HIV (PLWH) with full virologic response to ART but impaired immune recovery, and establish the relative frequency of terms and criteria used. We discuss the terms and criteria used and suggest possibilities for a consensual definition, aiming to establish grounds for further discussions to reach consensus. For convenience, we use the term “immunological nonresponse” (INR), as it was the most frequently used term on the included studies.

METHODS

This systematic review was conducted according to PRISMA practice standards. The manuscript follows PRISMA and MOOSE checklists,23,24 adapted as needed. The review protocol was not registered in PROSPERO, because a review of definitions, rather than outcomes, does not fit the database format.

Records were retrieved from PubMed, using a search strategy that combined MeSH terms and common expressions used to describe PLWH with impaired immune recovery despite virologic suppression during ART (available in the Supplementary Material). After abstract and title screening, all studies or reports that used the concept of INR, published in English between January 2009 and September 2018, were included, unless they addressed pediatric or pregnant women populations.

A single representative term for INR was selected from each publication. Terms used in the different publications were then compared and summarized in a table. We also summarized the criteria to define INR used in the different studies. These included at least one immune recovery surrogate and at least one threshold value for that surrogate. Criteria were considered combined when including more than one surrogate or more than one threshold value, simultaneously or alternatively. Time points to assess INR status were expressed in time after ART initiation or in time of virologic suppression, in weeks, months, or years. To simplify comparison, we converted all timepoints to months. Records were then grouped by similar criteria, and 2 tables listing single and combined criteria were produced. In these tables, 2 types of frequencies were included for each criterion: n = absolute frequency, and ni = frequency considering only independent publications (ie, with no authors in common).

Procedures used for record search, screening, and data analysis are described in detail in the Supplementary Material.

RESULTS

On October 26, 2018, the PubMed search yielded 1360 documents sourced from 345 journals. Fifteen additional documents were included based on expert recommendations. Two independent reviewers screened titles and abstracts of the 1375 documents and excluded 1251 that were beyond the scope of this review. Twenty-one additional documents were excluded after full-text assessment because of: absence of virologic suppression (n = 6); severe lack of information (n = 2); and definition criteria not explicit (n = 12). Final analyses of INR definition included 103 publications (Fig. 1 and see Table S1, Supplemental Digital Content, http://links.lww.com/QAI/B373).

FIGURE 1.
FIGURE 1.:
PRISMA flow diagram of identification and selection of studies for the systematic review. Adapted from Moher et al.23

The 103 included studies were published in 41 peer reviewed journals, mainly in the scope of Immunology, Infectious Diseases, and/or Virology (Scopus sub-subject areas) (see Table S2, Supplemental Digital Content, http://links.lww.com/QAI/B373). Most studies (78%) were in journals ranked Q1 by CiteScore in at least one of their attributed sub-subjects in 2017.

Studies were evenly distributed across the years (see Figure S1, Supplemental Digital Content, http://links.lww.com/QAI/B373). Nine studies focused exclusively on men (n = 8; 8%) or women (n = 1; 1%). All other studies (n = 94; 91%) included participants of both sexes, with a male percentage between 24% and 97% (median 79%, interquartile range 19%).

Seven studies (7%) corresponded to international projects, including large collaborations/consortia (see Table S3, Supplemental Digital Content, http://links.lww.com/QAI/B373). The other 96 studies (93%) enrolled participants from 30 different countries. These were mostly (n = 25; 83%) upper -middle- and high-income countries according to the 2017 World Bank classification (see Tables S4 and S5, Supplemental Digital Content, http://links.lww.com/QAI/B373). Studies from upper-middle- and high-income countries had higher percentage of males than studies from low and lower-middle income countries (see Figure S2, Supplemental Digital Content, http://links.lww.com/QAI/B373).

All terms applied to INR in the 103 publications presented 2 elements: (1) an adjective (eg, “discordant,” “inadequate,” “immunological,” “impaired,” “poor,” or “suboptimal”) and (2) a noun to describe the alterations in immunologic state of PLWH during ART (eg, “reconstitution,” “recovery,” “response,” or “restoration”). Terms that included “CD4” (eg, “CD4 T cell-recovery,” and “CD4 T cell repopulation”) were separated from the terms that used a less specific expression (eg, “immune reconstitution,” and “immunological response”). Terms with common adjectives or nouns were then grouped, resulting in 22 different categories (Table 1). When all orthographic variations and synonyms were considered, more than 50 different expressions were obtained. Considering only the set of 22 categorical terms (T.), the 3 more frequent were: “immunological non-responders” (n = 24, T.6 in Table 1); “discordant immunological response” (n = 18, T.3 in Table 1), and “suboptimal CD4+ T-cell recovery” (n = 9, T.20 in Table 1).

TABLE 1.
TABLE 1.:
Terminology Used to Designate Immunological Non-Responders in the Included Publications

To understand whether the same authors contributed with multiple instances of the same term, the frequency of each term in publications with no authors in common was also analyzed (ni in Table 1). In this case, the most frequent expressions were still “immunological non-responders” (ni = 15, T.6 in Table 1) and “discordant immunological response” (ni = 9, T.3 in Table 1), followed by “suboptimal CD4+ T-cell recovery” and “poor CD4+ T cell recovery” (both with ni = 7, T.18 and T.20 in Table 1, respectively). As expected, publications with authors in common tended to share similar terms. In a few cases, publications with authors in common used different terms (eg, “immunological non-responders,” “low CD4 T-cell reconstitution,” and “poor CD4+ cell recovery” in Refs. 13,25,26).

The 103 studies included 73 different criteria to classify INR individuals. Of these, 48 (66%) were single criteria, defined as not reaching a single threshold of a single surrogate, and 25 (34%) were combined criteria, defined as multiple conditions considered simultaneously (AND) or alternatively (OR). All criteria used CD4+ T-cell counts to evaluate immune recovery during ART, either as absolute number, in 59 of the 73 criteria (81%; C.1-C.35 in Table 2, and C.49-C.68 and C.70-C.73 in Table 3), or as the change in CD4+ T-cell count compared with a baseline value, in the remaining 14 criteria (19%; C.36-C.48 in Table 2 and C.69 in Table 3). Of the 59 criteria that used absolute CD4+ T-cell counts as surrogate of the immune recovery, 38 (64%) were single criteria. In the other 21 (36%), the absolute CD4+ T-cell count was combined with CD4+ T-cell count change, and/or CD4/CD8 ratio.

TABLE 2.
TABLE 2.:
Single Criteria to Select Immunological Non-Responders in the Included Publications
TABLE 3.
TABLE 3.:
Combined Criteria to Select Immunological Non-Responders in the Included Publications

Fifty-eight criteria were unique, and only 15 were used in more than one study. Of these, only 9 were used by groups with no authors in common (C.9, C.10, C.20-C.23, C.33, C.45, and C.61 in Tables 2 and 3). The 3 most used criteria considered CD4+ T-cell counts <350 cells/µL after ≥24 months of virologic suppression (n = 8, C.22 in Table 2); <250 cells/µL after ≥24 months of virologic suppression (n = 5, C.12 in Table 2); and <350 cells/µL after ≥24 months of ART (n = 4, C.21 in Table 2).

The most frequently used thresholds were “<350 cells/µL” (n = 35) and “<200 cells/µL” (n = 22), evaluated “at or after at least 12 months” (n = 36) of ART or virologic suppression and “at or after at least 24 months” (n = 35) of ART or virologic suppression.

DISCUSSION

Terms standardization is as old as human language, and assumes particular relevance in the context of scientific communication.27 In 1986, to avoid the multiplicity of names used for the “AIDS virus” (Human T-lymphotropic virus III (HTLV-III); lymphadenopathy-associated virus; immunodeficiency-associated virus; and AIDS associated retrovirus), the International Committee for the Taxonomy of Viruses recommended the use of the term “human immunodeficiency virus” and of the abbreviation “HIV.”28 This consensus was essential to expand scientific knowledge on HIV.

PLWH on ART who experience unsatisfactory immune recovery despite full virologic suppression have higher morbidity and mortality,9 but the data on these individuals are difficult to combine because of the lack of a standardized case definition.11,22 Although previous reviews mentioned or discussed this problem,22,29,30 or addressed clinical outcomes,11 this is the first to systematically analyze INR terminology and defining criteria.

Our results show striking diversity in terms and definitions used in the literature. This diversity may be even higher because some publications included several different expressions used interchangeably throughout the text, from which we analyzed only the most representative. The meaning of each term found in this review may generate different interpretations. Furthermore, some abbreviations are commonly used with a different meaning in the clinical context (e.g., “INR” for “international normalized ratio”). These problems are discussed in detail in the supplementary material (see Table S6, Supplemental Digital Content, http://links.lww.com/QAI/B373).

Seventy-three different criteria to define INR were found. Most studies (81%) used CD4+ T-cell counts and only 19% used the change compared with baseline. In a review article, Cenderello and De Maria22 have explained the limitations of each situation, which are related to grouping together different recovery patterns. The use of CD4+ T-cell count threshold to define INR pools together individuals who started with different values (eg, <100 and 200–350 cells/µL), but achieved the same CD4+ T-cell counts at a determined time point, although they present different CD4+ T-cell count trajectories. But the use of CD4+ T-cell count change groups individuals who started with different CD4+ T-cell counts, although they present different immune recovery dynamics.

Regarding the 3 most frequent criteria, 2 used a threshold of 350 cells/µL, and 2 used the time point ≥24 months of virologic suppression. Theoretically, lower thresholds and distant time points are more restrictive, and tend to narrow the concept of INR. For example, fewer PLWH are expected to have “CD4+ T-cell count <250 cells/µL after ≥12 months of ART” than those with “CD4+ T-cell count <350 cells/µL after ≥12 months of ART” or “CD4+ T-cell count <250 cells/µL after ≥6 months of ART.” However, all these criteria identify groups with a presumable higher risk of morbidity and mortality when compared with groups with higher CD4+ T cell-counts at the same time point.11 Earlier time points are less restrictive and may lead to include PLWH with slower immune response, who may reach normal CD4+ T-cell counts after a longer period. This may lead to spend resources in PLWH with better prognosis (compared with those with more restrictive INR criteria), and to biased conclusions in clinical trials (eg, underestimating INR impact in the clinical outcome; no benefit of closer follow-up, treatment intensification, or new therapeutic strategies in INR compared with controls). Nonetheless, earlier time points allow earlier and more impactful interventions.

To define a standard criterion, one needs to first discuss how restrictive it must be to represent the true clinical outcome of these individuals. A standard definition should also clearly state whether the time point is considered from the beginning of ART or of virologic suppression, and in the latter, how virologic suppression should be assessed. “Persistent virologic suppression” is a subjective expression because of the occurrence of blips. A good example of a clear virologic suppression definition, from Pacheco et al,31 is “all viral load measurements during this period (first 2 years of ART) <500 copies/mL, allowing for exceptions during the first 24 weeks,” although the threshold should be <50 instead of <500 copies/mL and viral blips should also be contemplated.

Pre-ART CD4+ T-cell counts influence the immune recovery pattern, and the lower the values at baseline, the more difficult it is to reach the threshold. Moreover, isolated CD4+ T-cell count measurements may not reflect the immune recovery pattern, because many factors, such as co-existing infections, influence the absolute CD4+ T-cell count at a given time point. Thus, a standard definition should also include the conditions under which PLWH meet or fail the criteria.

Other parameters may also be useful to classify ART response based on the immune recovery. Cenderello and De Maria22 suggested including age, nadir CD4+ T-cell count, CD4/CD8 ratio, and presence of AIDS-defining and non-AIDS-defining events in the classification of ART response based on the immune recovery. ART status (naive vs. experienced), baseline viral load, and other immunologic parameters could also have prognostic value.32–35 INR individuals could benefit from a prognostic index including these and/or other parameters, similar to the International Prognostic Index for patients with aggressive non-Hodgkin lymphoma.36

Although CD4+ T-cell count change over the first few months is important for PLWH initiating ART, absolute counts are more relevant for PLWH on ART for many years, because the increase in CD4+ T-cell counts is expected to be higher in the first months than after 24 months of ART.4 Individuals with low CD4+ T-cell counts at diagnosis, with or without opportunistic infections, are more likely to develop INR over time. Although some of these individuals may be able to normalize their immune system during ART, lower initial increases in CD4+ T cell-counts presumably preclude recovery to normal levels. Taking this into consideration, we propose 2 criteria to be applied to PLWH with CD4+ T-cell counts below a specific cut-off (eg, <200 cells/µL) at ART initiation, identifying different INR stages: (1) a CD4+ T-cell count change <50 cells/µL assessed at a relatively early time point (eg, 6 months of ART) identifies individuals at high risk of developing INR over time; and (2) an absolute CD4+ T-cell count <350 cells/µL after an extended period on ART (eg, ≥24 months of ART) identifies INR individuals whose CD4+ T-cell counts should have already reached their maximum potential and remain below the expected values. These definitions should be validated in large studies.

One strength of this review is the transparent and comprehensive search strategy, encompassing a large set of terms. As limitations, the publication search was restricted to one search engine, and a set of search terms had to be defined a priori, so the existence of other terminologies cannot be excluded. However, the latter limitation was partially overcome by the broadness of the search strategy. Records published before 2009 were not considered because they may include terms and criteria that have fallen into disuse. Although a structured quality analysis of the included studies is not described, the fact that most studies were published in journals ranked Q1 by CiteScore assures, at least in part, the study quality. Future research should also include analysis of nadir CD4+ T-cell counts, ART schemes, and clinical outcomes. In addition, 2 important gaps identified in this review should also be addressed: most studies report data from upper-middle- and high-income countries, as also observed by Kelly et al11; and samples from upper-middle- and high-income countries include more males than samples from low and lower-middle income countries, thus introducing gender differences when comparing these 2 settings.

A standard term and consensual defining criteria for INR that are supported by the HIV clinical and research community are urgently needed.11,22,27,32 To achieve those, we suggest a similar process as the one undertaken by the Sedentary Behavior Research Network for standardization of the terminology and definitions related to sedentary behaviors.37 The process consisted of a literature review by an expert committee to identify and modify key terms; then, Sedentary Behavior Research Network members provided feedback on the proposed terms and draft definitions through an online survey, ultimately leading to consensual definitions, including caveats and examples. To follow this example, the main HIV international associations could join efforts to nominate a committee of experts or working group to propose a consensual INR term and definition criteria. The participation and feedback of professionals and researchers in the field would favor the wide support and adoption of the proposed term and definition. After adoption of a consensual term and criteria, clinical outcomes of INR individuals could be assessed by determining the risk of mortality, AIDS or serious non-AIDS events. Sex differences, age, and other confounding variables should be analyzed by subgroup analysis in large prospective studies.

This review raises awareness on the diversity of terminologies and criteria for INR found in the literature, and may serve as a basis for decision-makers, researchers, and clinicians to discuss this problem. Standardization of INR terminology and criteria could lead to new interventions, policies, and practices to improve prognosis of PLWH.

REFERENCES

1. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir Res. 2010;85:1–18.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
3. Kasper DL, Fauci AS, Hauser SL, et al. Harrison's Principles of Internal Medicine. 19th ed. New York, NY: McGraw Hill Education; 2015.
4. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood. 2011;117:5582–5590.
5. Hughes RA, May MT, Tilling K, et al. Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio ART Cohort Collaboration (ART-CC) Study. AIDS. 2018;32:1361–1367.
6. Le Moing V, Thiébaut R, Chêne G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007;8:156–163.
7. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441–446.
8. Lok JJ, Bosch RJ, Benson CA, et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS. 2010;24:1867–1876.
9. AIDS Info. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2014. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed August 2, 2019.
10. Society EAC. EACS Guidelines 2018—Version 9.1. 2018. Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed August 2, 2019.
11. Kelly C, Gaskell KM, Richardson M, et al. Discordant immune response with antiretroviral therapy in HIV-1: a systematic review of clinical outcomes. PLoS One. 2016;11:e0156099.
12. Valdés-Ferrer SI, Crispín JC, Belaunzarán-Zamudio PF, et al. Add-on pyridostigmine enhances CD4+ T-cell recovery in HIV-1-Infected immunological non-responders: a proof-of-concept study. Front Immunol. 2017;8:1301.
13. Thiébaut R, Jarne A, Routy JP, et al. Repeated cycles of recombinant human interleukin 7 in HIV-infected patients with low CD4 T-cell reconstitution on antiretroviral therapy: results of 2 phase II multicenter studies. Clin Infect Dis. 2016;62:1178–1185.
14. van Lelyveld SFL, Drylewicz J, Krikke M, et al. Maraviroc intensification of cART in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial. PLoS One. 2015;10:e0132430.
15. Nakanjako D, Ssinabulya I, Nabatanzi R, et al. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health. 2015;20:380–390.
16. Cillo AR, Hilldorfer BB, Lalama CM, et al. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4(+) T-cell recovery. AIDS. 2015;29:2121–2129.
17. Somsouk M, Dunham RM, Cohen M, et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS One. 2014;9:e116306.
18. Rusconi S, Vitiello P, Adorni F, et al. Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. PLoS One. 2013;8:e80157.
19. Joly V, Fagard C, Grondin C, et al. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother. 2013;57:758–765.
20. Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4(+) T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012;206:534–542.
21. Marchetti G, Meroni L, Varchetta S, et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus–positive patients with advanced immune impairment. J Infect Dis. 2002;186:606–616.
22. Cenderello G, De Maria A. Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects. Expert Rev Anti Infect Ther. 2016;14:29–40.
23. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
24. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.
25. Lu W, Feng Y, Jing F, et al. Association between gut microbiota and CD4 recovery in HIV-1 infected patients. Front Microbiol. 2018;9:1451.
26. Jacobson JM, Wang H, Bordi R, et al. A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4(+) T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;66:399–406.
27. Slisko J, Dykstra DI Jr. The role of scientific terminology in research and teaching: is something important missing? J Res Sci Teach. 1997;34:655–660.
28. Coffin J, Haase A, Levy JA, et al. Human immunodeficiency viruses. Science. 1986;232:697.
29. Massanella M, Negredo E, Clotet B, et al. Immunodiscordant responses to HAART—mechanisms and consequences. Expert Rev Clin Immunol. 2013;9:1135–1149.
30. Gaardbo JC, Hartling HJ, Gerstoft J, et al. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol. 2012;2012:670957.
31. Pacheco YM, Jarrin I, Rosado I, et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antivir Res. 2015;117:69–74.
32. Menkova-Garnier I, Hocini H, Foucat E, et al. P2X7 receptor inhibition improves CD34 T-cell differentiation in HIV-infected immunological nonresponders on c-ART. PLoS Pathog. 2016;12:e1005571.
33. Saison J, Ferry T, Demaret J, et al. Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol. 2014;176:401–409.
34. Valiathan R, Asthana D. Increase in frequencies of circulating Th-17 cells correlates with microbial translocation, immune activation and exhaustion in HIV-1 infected patients with poor CD4 T-cell reconstitution. Immunobiology. 2016;221:670–678.
35. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–1543.
36. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994.
37. Tremblay MS, Aubert S, Barnes JD, et al. Sedentary behavior research Network (SBRN)—terminology consensus project process and outcome. Int J Behav Nutr Phys Act. 2017;14:75.
38. Fernandez S, Tanaskovic S, Helbig K, et al. CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. J Infect Dis. 2011;204:1927–1935.
39. Shmagel NG, Shmagel KV, Saidakova EV, et al. Discordant response of CD4+ T cells to antiretroviral therapy in HIV-infected patients coinfected with hepatitis C virus is accompanied by increased liver damage. Dokl Biochem Biophys. 2015;465:358–360.
40. Asdamongkol N, Phanachet P, Sungkanuparph S. Low plasma zinc levels and immunological responses to zinc supplementation in HIV-infected patients with immunological discordance after antiretroviral therapy. Jpn J Infect Dis. 2013;66:469–474.
41. Casotti JAS, Passos LN, de Oliveira FJP, et al. Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil. Rev Inst Med Trop Sao Paulo. 2011;53:301–307.
42. Gilson RJ, Man SL, Copas A, et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med. 2010;11:152–160.
43. Gómez-Mora E, Massanella M, García E, et al. Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS One. 2017;12:e0184433.
44. Kayigamba FR, Franke MF, Bakker MI, et al. Discordant treatment responses to combination antiretroviral therapy in Rwanda: a prospective cohort study. PLoS One. 2016;11:e0159446.
45. Loutfy MR, Genebat M, Moore D, et al. A CD4(+) cell count < 200 cells per cubic millimeter at 2 Years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Def Syndr. 2010;55:451–459.
46. Massanella M, Gómez-Mora E, Carrillo J, et al. Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. J Transl Med. 2015;13:230.
    47. Massanella M, Negredo E, Pérez-Álvarez N, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS. 2010;24:959–968.
    48. Massanella M, Negredo E, Puig J, et al. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. AIDS. 2012;26:2285–2293.
    49. Mingbunjerdsuk P, Asdamongkol N, Sungkanuparph S. Factors associated with immunological discordance in HIV-infected patients receiving antiretroviral therapy with complete viral suppression in a resource-limited setting. Jpn J Infect Dis. 2015;68:301–304.
    50. Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis. 2010;50:1300–1308.
    51. Perez-Santiago J, Ouchi D, Urrea V, et al. Antiretroviral therapy suppressed participants with low CD4(+) T-cell counts segregate according to opposite immunological phenotypes. AIDS. 2016;30:2275–2287.
    52. Sachdeva N, Weinstein JE, Ashman M, et al. Poor lymphoproliferative responses with low proportion of Gag-specific CD8 TEMRA cells in HIV-1-infected patients showing immunological and virological discordance despite prolonged suppression of plasma viremia. Viral Immunol. 2010;23:49–61.
    53. Zoufaly A, an der Heiden M, Kollan C, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis. 2011;203:364–371.
    54. Zoufaly A, Cozzi-Lepri A, Reekie J, et al. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in europe. PLoS One. 2014;9:e87160-e.
    55. Julg B, Poole D, Ghebremichael M, et al. Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One. 2012;7:5.
      56. Negredo E, Massanella M, Puertas MC, et al. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. J Antimicrob Chemother. 2013;68:2358–2362.
      57. Raffi F, Le Moing V, Assuied A, et al. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. J Antimicrob Chemother. 2017;72:240–245.
      58. Darraj M, Shafer LA, Chan S, et al. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression. J Infect Public Health. 2018;11:265–269.
      59. Shive CL, Clagett B, McCausland MR, et al. Inflammation perturbs the IL-7 Axis, promoting senescence and exhaustion that broadly characterize immune failure in treated HIV infection. J Acquir Immune Def Syndr. 2016;71:483–492.
      60. Anude CJ, Eze E, Onyegbutulem HC, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013;13:113.
      61. Bandera A, Masetti M, Fabbiani M, et al. The NLRP3 inflammasome is upregulated in HIV-infected antiretroviral therapy-treated individuals with defective immune recovery. Front Immunol. 2018;9:8.
        62. Bellistrì GM, Casabianca A, Merlini E, et al. Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy. PLoS One. 2010;5:e15663.
        63. De Benedetto I, Masetti M, Fabbiani M, et al. Higher levels of peripheral Th17 T CD4+ cells are associated with immunological non response in HIV-infected patients under effective ART. J Acquir Immune Def Syndr. 2018;77:e45–e47.
        64. Engsig FN, Gerstoft J, Kronborg G, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis. 2010;10:318.
        65. Gaardbo JC, Hartling HJ, Ronit A, et al. Regulatory T cells in HIV-infected immunological nonresponders are increased in blood but depleted in lymphoid tissue and predict immunological reconstitution. J Acquir Immune Def Syndr. 2014;66:349–357.
        66. Girard A, Vergnon D, Depincé-Berger AE, et al. A high rate of β7+ gut homing lymphocytes in HIV infected Immunogical Non Responders is associated with poor CD4 T cell recovery during suppressive HAART. J Acquir Immune Defic Syndr. 2016;72:259–265.
        67. Horta A, Nobrega C, Amorim-Machado P, et al. Poor immune reconstitution in HIV-infected patients associates with high percentage of regulatory CD4(+) T cells. PLoS One. 2013;8:e57336.
        68. Kye-Hyung K, Jongyoun Y, Sun Hee L. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study. Korean J Intern Med. 2015;30:705–713.
        69. Li T, Xie J, Li YY, et al. Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety. HIV Clin Trials. 2015;16:49–56.
        70. Magen E, Elbirt D, Agmon-Levin N, et al. Eradication of Helicobacter pylori can facilitate immune reconstitution in HIV-1-infected immunological non-responders. Int J Infect Dis. 2010;14:E322–E327.
        71. Marchetti G, Gazzola L, Trabattoni D, et al. Skewed T-cell maturation and function in HIV-infected patients failing CD4+recovery upon long-term virologically suppressive HAART. AIDS. 2010;24:1455–1460.
        72. Merlini E, Bai F, Bellistri GM, et al. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One. 2011;6:e18580.
        73. Minami R, Takahama S, Kaku Y, et al. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery. J Infect Chemother. 2017;23:29–34.
        74. Mupfumi L, Moyo S, Molebatsi K, et al. Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana. PLoS One. 2018;13:e0192030.
        75. Rodríguez-Gallego E, Gómez J, Pacheco YM, et al. A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. AIDS. 2018;32:565–573.
        76. Routy JP, Angel JB, Patel M, et al. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16:48–56.
        77. Saidakova EV, Korolevskaya LB, Shmagel NG, et al. The role of interleukin 7 and its cell receptor in a poor recovery of CD4+ T cells in HIV-infected patients receiving antiretroviral therapy. Dokl Biol Sci. 2014;458:313–315.
        78. Sennepin A, Baychelier F, Guihot A, et al. NKp44L expression on CD4+ T cells is associated with impaired immunological recovery in HIV-infected patients under highly active antiretroviral therapy. AIDS. 2013;27:1857–1866.
        79. Soria A, Guerini FR, Bandera A, et al. KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy. PLoS One. 2011;6:e27349.
        80. Stiksrud B, Lorvik KB, Kvale D, et al. Plasma IP-10 is increased in immunological NonResponders and associated with activated regulatory T cells and persisting low CD4 counts. J Acquir Immune Def Syndr. 2016;73:138–148.
        81. Tincati C, Merlini E, Braidotti P, et al. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4(+) T-cell recovery upon virologically suppressive combination antiretroviral therapy. AIDS. 2016;30:991–1003.
        82. Erikstrup C, Kronborg G, Lohse N, et al. T-cell dysfunction in HIV-1-Infected patients with impaired recovery of CD4 cells despite suppression of viral replication. J Acquir Immune Def Syndr. 2010;53:303–310.
        83. Stepanyuk O, Chiang TS, Dever LL, et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS. 2009;23:1911–1922.
        84. Tasca KI, Correa CR, Caleffi JT, et al. Asymptomatic HIV people present different profiles of sCD14, sRAGE, DNA damage, and vitamins, according to the use of cART and CD4+ T cell restoration. J Immunol Res. 2018;2018:11.
        85. Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 Years with incomplete CD4 recovery. Clin Infect Dis. 2014;58:1312–1321.
        86. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4(+) T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203:1474–1483.
        87. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD41 T-cell recovery: a randomized trial. Blood. 2013;121:4635–4646.
        88. Falster K, Petoumenos K, Chuah J, et al. Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. J Acquir Immune Def Syndr. 2009;50:307–313.
        89. Su Qj, Li Yz, Liang Fl, et al. Polyactin A increases CD4+ T-cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy. Int J STD AIDS. 2014;25:24–28.
        90. Cuzin L, Trabelsi S, Delobel P, et al. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Def Syndr. 2012;61:557–564.
        91. Méndez-Lagares G, Pozo-Balado MM, Genebat M, et al. Severe immune dysregulation affects CD4+CD25hiFoxP3+ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J Infect Dis. 2012;205:1501–1509.
        92. Mendez-Lagares G, Garcia-Perganeda A, del Pozo-Balado MD, et al. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. J Antimicrob Chemother. 2012;67:1228–1237.
        93. Molina-Pinelo S, Vallejo A, Diaz L, et al. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation. J Antimicrob Chemother. 2009;64:579–588.
        94. Pacheco YM, Jarrín I, Del Amo J, et al. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr HIV Res. 2009;7:612–619.
        95. Rosado-Sanchez I, Herrero-Fernandez I, Genebat M, et al. HIV-infected subjects with poor CD4 T-cell recovery despite effective therapy express high levels of OX40 and alpha4beta7 on CD4 T-cells prior therapy initiation. Front Immunol. 2018;9:1673.
          96. Rosado-Sanchez I, Herrero-Fernandez I, Alvarez-Rios AI, et al. A lower baseline CD4/CD8 T-cell ratio is independently associated with immunodiscordant response to antiretroviral therapy in HIV-infected subjects. Antimicrob Agents Chemother. 2017;61:6.
            97. Rosado-Sanchez I, Jarrin I, Pozo-Balado MM, et al. Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery. Antivir Res. 2017;142:76–82.
            98. Grabmeier-Pfistershammer K, Steinberger P, Rieger A, et al. Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Def Syndr. 2011;56:118–124.
            99. Casotti JAS, Passos LN, Oliveira FJP, et al. Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study. BMC Infect Dis. 2011;11:11.
            100. Giuliani E, Vassena L, Di Cesare S, et al. NK cells of HIV-1-infected patients with poor CD4+ T-cell reconstitution despite suppressive HAART show reduced IFN-γ production and high frequency of autoreactive CD56bright cells. Immunol Lett. 2017;190:185–193.
            101. Takuva S, Maskew M, Brennan AT, et al. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014;17:18651.
              102. Lichtenstein KA, Armon C, Nagabhushanam V, et al. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther. 2012;17:1301–1309.
              103. Tanaskovic S, Fernandez S, French M, et al. Thymic tissue is not evident on high-resolution computed tomography and [18F]Fluoro-deoxy- glucose positron emission tomography scans of aviraemic HIV patients with poor recovery of CD4R T cells. AIDS. 2011;25:1235–1237.
              104. Woelk CH, Beliakova-Bethell N, Goicoechea M, et al. Gene expression before haart initiation predicts hiv-infected individuals at risk of poor cd4+ t-cell recovery. AIDS. 2010;24:217–222.
              105. Helleberg M, Kronborg G, Larsen CS, et al. Poor CD4 response despite viral suppression is associated with increased non-AIDS-related mortality among HIV patients and their parents. AIDS. 2013;27:1021–1026.
              106. Logerot S, Rancez M, Charmeteau-de Muylder B, et al. HIV reservoir dynamics in HAART-treated poor immunological responder patients under IL-7 therapy. AIDS. 2018;32:715–720.
              107. Gunda DW, Kilonzo SB, Kamugisha E, et al. Prevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study. BMC Res Notes. 2017;10:197.
                108. El-Beeli M, Al-Mahrooqi SH, Youssef RM, et al. HLA-A68 and HLA-B15 alleles correlate with poor immune response among AIDS patients on combined antiretroviral therapy. Hum Immunol. 2016;77:490–497.
                109. Rallon N, Sempere-Ortells JM, Soriano V, et al. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. J Antimicrob Chemother. 2013;68:2616–2625.
                110. Van Lelyveld SFL, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012;26:465–474.
                111. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One. 2009;4:e7658.
                112. Wojcik-Cichy K, Piekarska A, Jablonowska E. Intestinal barrier impairment and immune activation in HIV-infected advanced late presenters are not dependent on CD4 recovery. Arch Immunol Ther Exp. 2018;66:321–327.
                113. Zhang FD, Sun MY, Sun JJ, et al. The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China. Biosci Trends. 2015;9:335–341.
                  114. Asmelash A, Zheng Y, Kaloustian KW, et al. Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa. BMC Infect Dis. 2014;14:331.
                  115. Byakwaga H, Kelly M, Purcell DFJ, et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis. 2011;204:1532–1540.
                  116. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4(+) T cell response. J Infect Dis. 2011;203:960–968.
                  117. Nakanjako D, Ssewanyana I, Mayanja-Kizza H, et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011;11:43.
                  118. Önen NF, Overton ET, Presti R, et al. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome. HIV Med. 2009;10:439–446.
                  119. Lee SC, Chua LL, Yap SH, et al. Enrichment of gut-derived Fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals. Sci Rep. 2018;8:14277.
                  120. Nakanjako D, Kiragga AN, Musick BS, et al. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. AIDS. 2016;30:1913–1922.
                  121. Batista G, Buvé A, Ngom Gueye NF, et al. Initial suboptimal CD4 reconstitution with antiretroviral therapy despite full viral suppression in a cohort of HIV-infected patients in Senegal. Med Mal Infect. 2015;45:199–206.
                  122. Bayigga L, Nabatanzi R, Sekiziyivu PN, et al. High CD56(++)CD16(-) natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort. BMC Immunol. 2014;15.
                    123. Hermans SM, Kiragga AN, Schaefer P, et al. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-saharan africa. PLoS One. 2010;5:e10527.
                    124. Nakanjako D, Ssewanyana I, Nabatanzi R, et al. Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort. BMC Immunol. 2013;14:26.
                    125. Choi JY, Zhou J, Giles M, et al. Predictors and outcomes of HIV-infected antiretroviral-naive patients with discordant responses to combination antiretroviral treatment in Asian and Australian populations: results from APHOD. J Acquir Immune Defic Syndr. 2011;57:13–20.
                      126. Tuboi SH, Pacheco AG, Harrison LH, et al. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr. 2010;53:70–77.
                      127. van Griensven J, Zachariah R, Rasschaert F, et al. Discordant immunologic and virologic responses to antiretroviral therapy and associated mortality in a large treatment program in Rwanda. J Acquir Immune Defic Syndr. 2009;50:556–558.
                      Keywords:

                      HIV infection; antiretroviral therapy; immune recovery; CD4+ T-cell count; immunological nonresponders; systematic review

                      Supplemental Digital Content

                      Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.